Recent advances in treatment of nodal and gastrointestinal follicular lymphoma

Table 3 Summary of clinical trial results of anti-programmed death ligand 1 antibody-based therapies

Study	Target disease	No. of patients	Objective response rate	Complete response rate	Median progression-free survival	Overall survival	Adverse events or other subjects	Ref.
Atezolitumab (anti-PD-1 antibody) plus obinutumab	Total	n = 49				Unknown		[31]
phase-I	r/r FL	n = 26	54%	23%	9 mo
	r/r DLBCL	n = 23	17%	4%	3 mo
Pembrolizumab(anti-PD-1antibody) plus rituximab	r/r FL (one or more prior therapy)	n = 30	67%	50%	12.6 mo	97% (at 3 yr)	23% in remission at medianfollow-up of 35 mo	[32]

“Unknown” means data not shown, unknown information or not reached. r/r: Refractory and relapsed; FL: Follicular lymphoma; DLBCL: Diffuse large B-cell lymphoma; PD-1: Programmed death ligand 1.